Press releases
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
- New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
- New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
- BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
More ▼
Key statistics
On Friday, Biomarin Pharmaceutical Inc (0HNC:LSE) closed at 74.30, 0.75% above its 52-week low of 73.75, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 74.30 |
Average volume | 242.75k |
---|---|
Shares outstanding | 189.88m |
Free float | 188.29m |
P/E (TTM) | 76.20 |
Market cap | 15.29bn USD |
EPS (TTM) | 1.06 USD |
Data delayed at least 15 minutes, as of May 31 2024 18:43 BST.
More ▼